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ABSTRACT
BACKGROUND: An increase in serious adverse events with both 
regular formoterol and regular salmeterol in chronic asthma has been 
demonstrated in comparison with placebo in previous Cochrane reviews. 
This increase was significant in trials that did not randomise participants 
to an inhaled corticosteroid, but less certain in the smaller numbers of 
participants in trials that included an inhaled corticosteroid in the ran-
domised treatment regimen.
OBJECTIVES: We set out to compare the risks of mortality and 
non-fatal serious adverse events in trials which have randomised patients 
with chronic asthma to regular formoterol versus regular salmeterol, when 
each are used with an inhaled corticosteroid as part of the randomised 
treatment
SEARCH STRATEGY: Trials were identified using the Cochrane 
Airways Group Specialised Register of trials. Manufacturers’ web sites of 
clinical trial registers were checked for unpublished trial data and Food 
and Drug Administration (FDA) submissions in relation to formoterol 
and salmeterol were also checked. The date of the most recent search 
was July 2009.
SELECTION CRITERIA: Controlled clinical trials with a parallel 
design, recruiting patients of any age and severity of asthma were included 
if they randomised patients to treatment with regular formoterol versus 
regular salmeterol (each with a randomised inhaled corticosteroid), and 
were of at least 12 weeks duration.
DATA COLLECTION AND ANALYSIS: Two authors indepen-
dently selected trials for inclusion in the review and extracted outcome 
data. Unpublished data on mortality and serious adverse events were 
sought from the sponsors and authors.
MAIN RESULTS: Eight studies met the eligibility criteria of the review 
recruiting 6,163 adults and adolescents. There were seven studies (involving 
5,935 adults and adolescents) comparing formoterol and budesonide to 
salmeterol and fluticasone. All but one study administered the products 
as a combined inhaler, and most used formoterol 50 mcg and budesonide 
400 mcg twice daily versus salmeterol 50 mcg and fluticasone 250 mcg 
twice daily. There were two deaths overall (one on each combination) and 
neither were thought to be related to asthma. There was no significant 
difference between treatment groups for non-fatal serious adverse events, 
either all-cause (Peto OR 1.14; 95% CI 0.82 to 1.59, I2 = 26%) or asthma-
related (Peto OR 0.69; 95% CI 0.37 to 1.26, I2 = 33%). Over 23 weeks 
the rates for all-cause serious adverse events were 2.6% on formoterol and 
budesonide and 2.3% on salmeterol and fluticasone, and for asthma-related 
serious adverse events, 0.6% and 0.8% respectively. There was one study 
(228 adults) comparing formoterol and beclomethasone to salmeterol and 
fluticasone, but there were no deaths or hospital admissions. No studies 
were found in children.
AUTHORS’ CONCLUSIONS: The seven identified studies in 
adults did not show any significant difference in safety between formot-
erol and budesonide in comparison with salmeterol and fluticasone. 
Asthma-related serious adverse events were rare, and there were no re-
ported asthma-related deaths. There was a single small study comparing 
formoterol and beclomethasone to salmeterol and fluticasone in adults, 
but no serious adverse events occurred in this study. No studies were 
found in children. Overall there is insufficient evidence to decide whether 
regular formoterol and budesonide or beclomethasone have equivalent 
or different safety profiles from salmeterol and fluticasone.
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COMMENTS
Inhalatory medications (inhalatory medications and bronchodila-
tors) are the basis for treatment of the stable phase of asthma and for 
chronic obstructive pulmonary disease (COPD). The pathogenesis of 
asthma results from an inflammatory process in the airways that leads 
to contraction of the smooth musculature and triggers the symptoms of 
coughing, expectoration and dyspnea. Therefore, the treatment for stable 
asthma is based on the use of inhalatory corticoids for all patients with 
persistent conditions (mild, moderate or severe). For some patients, this is 
used in association with long-duration bronchodilators (LABAs) because 
of the clinical and functional state (spirometry). Inhalatory corticoids 
include beclomethasone, budesonide, fluticasone and ciclesonide, while 
formoterol and salmeterol are LABAs. Through previous systematic 
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reviews, it has been demonstrated that use of LABAs alone may lead to 
higher mortality among asthma patients.
The aim of this systematic review was to compare occurrences of 
mortality and non-fatal severe adverse effects in clinical trials that ran-
domized patients with asthma to make regular use of formoterol versus 
regular use of salmeterol, used in association with inhalatory corticoid 
as part of the randomized treatment. Eight studies were assessed in the 
systematic review, totaling 6,163 patients studied. The associations studied 
were formoterol + budesonide, salmeterol + fluticasone and formoterol 
+ beclomethasone.
There were two deaths in the studies, but none related to asthma. 
There was no significant difference between the treatment groups regard-
ing occurrences of non-fatal severe adverse effects, either for all causes 
(2.6% in the formoterol group and 2.3% in the salmeterol group) or for 
asthma-related causes (0.6% in the formoterol group and 0.8% in the 
salmeterol group). No studies on children were found. Only one study 
evaluating the association between formoterol and beclomethasone was 
found, but there were no severe adverse effects or deaths in this study.
The studies evaluated in this systematic review did not show any sig-
nificant difference regarding safety between the associations of formoterol 
+ budesonide and salmeterol +  fluticasone. Severe adverse events were 
rare and there were no asthma-related deaths.
Therefore, through this systematic review, it can be concluded that the 
use of inhalatory corticosteroid with LABA is safe and that it constitutes 
an excellent therapeutic alternative for patients with persistent asthma. 
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